Janux Therapeutics Inc [NASDAQ: JANX] gained 1.62% or 0.39 points to close at $24.45 with a heavy trading volume of 302430 shares.
It opened the trading session at $24.31, the shares rose to $24.87 and dropped to $23.95, the range by which the price of stock traded the whole day. The daily chart for JANX points out that the company has recorded -53.43% loss over the past six months.
If we look at the average trading volume of 974.86K shares, JANX reached to a volume of 302430 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Janux Therapeutics Inc [JANX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JANX shares is $88.55 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JANX stock is a recommendation set at 1.15. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Janux Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 03, 2024. While these analysts kept the previous recommendation, BTIG Research dropped their target price from $82 to $100. The new note on the price target was released on December 03, 2024, representing the official price target for Janux Therapeutics Inc stock. Previously, the target price had yet another raise to $79, while Leerink Partners analysts kept a Outperform rating on JANX stock.
The Price to Book ratio for the last quarter was 1.43, with the Price to Cash per share for the same quarter was set at 17.14.
Trading performance analysis for JANX stock
Janux Therapeutics Inc [JANX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.95. With this latest performance, JANX shares dropped by -3.85% in over the last four-week period, additionally sinking by -53.43% over the last 6 months – not to mention a drop of -54.33% in the past year of trading.
Janux Therapeutics Inc [JANX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Janux Therapeutics Inc [JANX] shares currently have an operating margin of -1216.61% and a Gross Margin at 78.07%. Janux Therapeutics Inc’s Net Margin is presently recorded at -832.71%.
Return on Equity for this stock declined to -8.94%, with Return on Assets sitting at -8.94%.
An analysis of Institutional ownership at Janux Therapeutics Inc [JANX]
There are presently around $117.03%, or 125.42% of JANX stock, in the hands of institutional investors. The top three institutional holders of JANX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 9.17 million shares, which is approximately 16.8326%. FMR LLC, holding 7.78 million shares of the stock with an approximate value of $$325.8 million in JANX stocks shares; and FMR LLC, currently with $$124.82 million in JANX stock with ownership which is approximately 5.4724%.
